FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Huizinga Robert Bindert
2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2021
3. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [AUPH]
(Last)
(First)
(Middle)
#1203-4464 MARKHAM STREET
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Ex Vice President of Research
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

VICTORIA, A1 V8Z7X8
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 103,592
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (1) 12/11/2022 Common Stock 16,000 $ 2.63 (2) D  
Stock Option (right to buy)   (3) 03/30/2021 Common Stock 40,000 $ 3.02 (2) D  
Stock Option (right to buy)   (4) 02/09/2027 Common Stock 110,000 $ 3.2 (2) D  
Stock Option (right to buy)   (5) 02/01/2028 Common Stock 225,000 $ 5.3 (2) D  
Stock Option (right to buy)   (6) 01/29/2029 Common Stock 70,000 $ 6.06 (2) D  
Stock Option (right to buy)   (5) 01/28/2030 Common Stock 61,100 $ 18.38 (2) D  
Stock Option (right to buy)   (7) 12/21/2030 Common Stock 93,593 $ 13.03 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Huizinga Robert Bindert
#1203-4464 MARKHAM STREET
VICTORIA, A1 V8Z7X8
      Ex Vice President of Research  

Signatures

/s/ Stephen Robertson, Attorney-in-Fact for Robert Bindert Huizinga 01/04/2021
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares subject to the option are fully vested and immediately exercisable. They vested in three equal monthly installments from the grant date.
(2) Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
(3) The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.
(4) The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date.
(5) The shares subject to the option vest in thirty-six equal monthly installments from the grant date.
(6) The shares subject to the option vest in twenty-four equal monthly installments from the grant date.
(7) One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.